Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 168
- Registration Number
- NCT01804985
- Locations
- 🇬🇧
University of Liveprool, Liverpool, United Kingdom
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 18
- Registration Number
- NCT01802450
- Locations
- 🇪🇸
Hospital Txagorritxu, Vitoria, Alava, Spain
🇪🇸Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
🇪🇸Hospital POVISA, Vigo, Pontevedra, Spain
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01751425
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dasatinib and Crizotinib in Advanced Cancer
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01744652
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 19
- Registration Number
- NCT01724879
- Locations
- 🇩🇪
University Hospital Düsseldorf, Düsseldorf, Germany
🇩🇪Asklepios Klinik St. Georg, Hamburg, Germany
🇩🇪Universitätsklinikum Großhadern, München, Germany
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 96
- Registration Number
- NCT01685125
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT01660906
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Promedica Hematology & Oncology Assoicates, Sylvania, Ohio, United States
🇰🇷Local Institution, Seoul, Korea, Republic of
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT01660971
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 44
- Registration Number
- NCT01652976
- Locations
- 🇺🇸
UF Health Cancer Center, Gainesville, Florida, United States
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01644773
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.